what is the cost of glp 1 drugs How much do GLP-1 without insurance? GLP-1 Drug Savings: A Complete

For local players, this reinforces the role of licensing and distribution alliances as a practical path to compete in the global #obesity market ahead of full-scale innovation or manufacturing build-out

Today, I spoke live with Paul Bagnell, news anchor with Bloomberg BNN, on the topic of the GLP-1 agonists and their impact on health care, industries beyond health and medicine, and consumers

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

GLP-1 microdosing and custom dosing require a PCAB-accredited sterile compounding pharmacy

Globally, 90% of diabetes patients have TIIDM

Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62